Propranolol: long-term treatment in narcolepsy-cataplexy

Area of Science:

• Neurology
• Pharmacology

Background:

• Narcolepsy is a chronic neurological disorder characterized by excessive daytime sleepiness.
• Current treatments for narcolepsy often have limitations or side effects.
• Propranolol, a beta-blocker, has been explored for potential therapeutic effects in narcolepsy.

Purpose of the Study:

• To evaluate the long-term efficacy and safety of propranolol in treating narcolepsy.
• To assess propranolol's impact on daytime sleepiness and vigilance in narcoleptic patients.

Main Methods:

• A study involving 48 narcoleptic patients treated with propranolol (80-240 mg/day) for an average of 18.4 months.
• Patients initially received propranolol monotherapy, with some later supplemented with tricyclics or stimulants.
• Vigilance tests and all-night polygraphic electroencephalogram recordings were used to assess treatment effects.

Main Results:

• Initial effectiveness of propranolol for daytime sleepiness was rated good to very good by 50% of patients.
• Effectiveness decreased significantly within 6 months, with only 8% satisfied with monotherapy after 26 months.
• Side effects included disturbed sleep, hypotension, lethargy, rash, and asthma, leading to a 58% dropout rate.

Conclusions:

• Propranolol demonstrates limited long-term efficacy as a sole treatment for narcolepsy.
• The drug's side effect profile contributes to a high discontinuation rate.
• While initial vigilance improved, sustained therapeutic benefit was not observed.